TMEM104 Inhibitors

Wiskostatin and Bafilomycin A1 target metabolic processes and vesicular acidification, respectively, which can impinge on the energy dynamics and endosomal function relevant to TMEM104's activity. Kinase inhibitors like Genistein and PD168393 obstruct phosphorylation events, which are often critical for protein activation, and could, therefore, modulate TMEM104's state of activity.

Other inhibitors, such as SB431542 and LY294002, target receptor kinases and PI3K, highlighting the role of growth factor signaling and lipid signaling in the regulation of TMEM104. The mTOR pathway, a central hub for cell growth and metabolism, can be inhibited by Rapamycin, implying that protein synthesis and other related processes are potentially important for TMEM104's role. Further, Y-27632 and Gö6983, which inhibit ROCK kinase and protein kinase C, respectively, indicate the relevance of cytoskeletal dynamics and protein phosphorylation in the functional regulation of TMEM104. U73122's inhibition of phospholipase C and PP2's targeting of Src family kinases suggest the involvement of lipid-derived messengers and proto-oncogenic pathways in TMEM104's regulation. Lastly, ZM 336372, by inhibiting RAF kinase, alludes to the MAPK signaling cascade as a regulatory influencer for TMEM104.